Next, to assess whether CAR-T cell therapy after LDRT was also effective in a different tumor model, we implemented a similar therapeutic approach in NSG mice implanted with the mesothelin-positive human CAPAN-2 cell line. The gene discussed is MSLN; the disease is neoplasm.